Cargando…
2015 Guidance on cancer immunotherapy development in early‐phase clinical studies
The development of cancer immunotherapies is progressing rapidly with a variety of technological approaches. They consist of “cancer vaccines”, which are based on the idea of vaccination, “effector cell therapy”, classified as passive immunotherapy, and “inhibition of immunosuppression”, which inten...
Ejemplares similares
-
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
por: Wang, Linan, et al.
Publicado: (2016) -
Tumor-specific donor lymphocyte infusion therapy with allogeneic T cells utilizing novel retrovirus vector silencing endogenous TCR expression
por: Ikeda, Hiroaki, et al.
Publicado: (2014) -
TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN
por: Temizoz, Burcu, et al.
Publicado: (2015) -
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells
por: Kitahata, Yuji, et al.
Publicado: (2016) -
Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use
por: Aoshi, Taiki, et al.
Publicado: (2015)